evidence table

Milk Thistle Liver Enzymes Randomized Trial Evidence Table

Structured evidence table for Milk Thistle Liver Enzymes Randomized Trial, generated from 1 reusable source document in the Migaku knowledge base.

topicclaimevidence levelcitationsource
Milk Thistle Liver Enzymes Randomized Trial1 2 1 3 4 5 6 Metabolic dysfunction-associated steatotic liver disease [MASLD; formerly known as non-alcoholic fatty liver disease (NAFLD)] is caused by chronic fat deposition in the liver and is the result of complex interactions involving metabolic dysregulation and insulin resistance ().2Messier Helen (2026)Effectiveness and safety of an ayurvedic nutraceutical for improving clinical parameters of liver function in participants with metabolic dysfunction-associated steatotic liver disease: a randomized, placebo-controlled, preliminary phase 2 exploratory clinical trial
Milk Thistle Liver Enzymes Randomized TrialSome patients with MASLD will have metabolic dysfunction-associated steatohepatitis (MASH) which is characterized by hepatocellular ballooning and lobular inflammation ().2Messier Helen (2026)Effectiveness and safety of an ayurvedic nutraceutical for improving clinical parameters of liver function in participants with metabolic dysfunction-associated steatotic liver disease: a randomized, placebo-controlled, preliminary phase 2 exploratory clinical trial
Milk Thistle Liver Enzymes Randomized TrialMASLD is associated with the development of cirrhosis, liver failure, liver cancer, and type 2 diabetes ().2Messier Helen (2026)Effectiveness and safety of an ayurvedic nutraceutical for improving clinical parameters of liver function in participants with metabolic dysfunction-associated steatotic liver disease: a randomized, placebo-controlled, preliminary phase 2 exploratory clinical trial
Milk Thistle Liver Enzymes Randomized TrialImaging tests, including FibroScan, which estimates the amount of fat and fibrosis present in the liver, are used to look for signs of MASLD ().2Messier Helen (2026)Effectiveness and safety of an ayurvedic nutraceutical for improving clinical parameters of liver function in participants with metabolic dysfunction-associated steatotic liver disease: a randomized, placebo-controlled, preliminary phase 2 exploratory clinical trial
topicMilk Thistle Liver Enzymes Randomized Trial
claim1 2 1 3 4 5 6 Metabolic dysfunction-associated steatotic liver disease [MASLD; formerly known as non-alcoholic fatty liver disease (NAFLD)] is caused by chronic fat deposition in the liver and is the result of complex interactions involving metabolic dysregulation and insulin resistance ().
evidence level2
citationMessier Helen (2026)
sourceEffectiveness and safety of an ayurvedic nutraceutical for improving clinical parameters of liver function in participants with metabolic dysfunction-associated steatotic liver disease: a randomized, placebo-controlled, preliminary phase 2 exploratory clinical trial
topicMilk Thistle Liver Enzymes Randomized Trial
claimSome patients with MASLD will have metabolic dysfunction-associated steatohepatitis (MASH) which is characterized by hepatocellular ballooning and lobular inflammation ().
evidence level2
citationMessier Helen (2026)
sourceEffectiveness and safety of an ayurvedic nutraceutical for improving clinical parameters of liver function in participants with metabolic dysfunction-associated steatotic liver disease: a randomized, placebo-controlled, preliminary phase 2 exploratory clinical trial
topicMilk Thistle Liver Enzymes Randomized Trial
claimMASLD is associated with the development of cirrhosis, liver failure, liver cancer, and type 2 diabetes ().
evidence level2
citationMessier Helen (2026)
sourceEffectiveness and safety of an ayurvedic nutraceutical for improving clinical parameters of liver function in participants with metabolic dysfunction-associated steatotic liver disease: a randomized, placebo-controlled, preliminary phase 2 exploratory clinical trial
topicMilk Thistle Liver Enzymes Randomized Trial
claimImaging tests, including FibroScan, which estimates the amount of fat and fibrosis present in the liver, are used to look for signs of MASLD ().
evidence level2
citationMessier Helen (2026)
sourceEffectiveness and safety of an ayurvedic nutraceutical for improving clinical parameters of liver function in participants with metabolic dysfunction-associated steatotic liver disease: a randomized, placebo-controlled, preliminary phase 2 exploratory clinical trial

Learn next

Related evidence and supplement guides

GuideMilk Thistle Fatigue Randomized Trial: What the Evidence SaysMilk Thistle Fatigue Randomized Trial has 2 source documents in the current Migaku evidence data...GuideMilk Thistle Fatigue Meta-analysis: What the Evidence SaysMilk Thistle Fatigue Meta-analysis has 2 source documents in the current Migaku evidence databas...GuideBerberine Liver Enzymes Meta-analysis: What the Evidence SaysBerberine Liver Enzymes Meta-analysis has 2 source documents in the current Migaku evidence data...GuideGrape Seed Exercise Recovery Randomized Trial: What the Evidence SaysGrape Seed Exercise Recovery Randomized Trial has 2 source documents in the current Migaku evide...AnswerDoes Grape Seed Exercise Recovery Randomized Trial work?Grape Seed Exercise Recovery Randomized Trial has evidence relevant to strength of evidence and...AnswerIs Grape Seed Exercise Recovery Randomized Trial safe?Grape Seed Exercise Recovery Randomized Trial has evidence relevant to safety, limits, and clini...AnswerWhat does the evidence say about Grape Seed Exercise Recovery Randomized Trial?Grape Seed Exercise Recovery Randomized Trial has evidence relevant to benefits, uncertainty, an...AnswerDoes Golden Kiwi Sleep Quality Randomized Trial work?Golden Kiwi Sleep Quality Randomized Trial has evidence relevant to strength of evidence and wha...

Source documents

  1. Effectiveness and safety of an ayurvedic nutraceutical for improving clinical parameters of liver function in participants with metabolic dysfunction-associated steatotic liver disease: a randomized, placebo-controlled, preliminary phase 2 exploratory clinical trial